Hidradenitis Suppurativa
main-banner
Hidradenitis Suppurativa
M1095-HS-302 Enrolling

Clinical Trial for Hidradenitis Suppurativa (52 Weeks)


Treatment: Injection Age: 18 Years


Who Can Participate?

Adults aged 18 and above diagnosed with hidradenitis suppurativa (HS) may participate.

Inclusion Criteria

  • Have had HS for more than 6 months
  • Have 5 or more abscesses or inflammatory nodules
  • Have HS lesions present in 2 or more distinct anatomical areas
  • Display inadequate response to appropriate systemic antibiotics for treatment of HS.

If you qualify, you may receive at no cost:

  • Access to the study drug
  • Close care and monitoring of your condition
  • The opportunity to help improve the treatment of HS

How Long Will The Study Last?

  • Around 52 weeks

Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

Dr. Melinda Gooderham

Dermatologist

Dr. Kirsten Walker

Dermatologist

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: June 23, 2024

Official Title

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

ClinicalTrials.gov ID

NCT06411379

Sponsor

MoonLake Immunotherapeutics AG

Study Description

  • Brief Summary:

    This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.

  • Condition or Disease:

    Hidradenitis Suppurativa

  • Intervention/Treatment:

    Drug: Sonelokimab
    Drug: Placebo
  • Phase:

    Phase 3

  • Ages Eligible for Study:

    18 Years and older (Adult)

  • Sexes Eligible for Study:

    All

Inclusion Criteria

  • Have had HS for more than 6 months
  • Have 5 or more abscesses or inflammatory nodules
  • Have HS lesions present in 2 or more distinct anatomical areas
  • Display inadequate response to appropriate systemic antibiotics for treatment of HS.

Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Hidradenitis Suppurativa

Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials
Skip to content